Clinical Application
Clinicopathological characteristics and therapeutic effects of adult rhabdomyosarcoma patients
Qiankun Yang, Shenglong Li, Tong Chen, Zhongxiang Yao, Xiaojing Zhang
Published 2019-11-23
Cite as Chin J Oncol, 2019, 41(11): 873-877. DOI: 10.3760/cma.j.issn.0253-3766.2019.11.014
Abstract
ObjectiveThis study aimed to investigate the clinicopathological characteristics and prognosis of adult rhabdomyosarcoma (RMS) patients.
MethodsThe clinical data of 34 adult RMS patients were retrospectively analyzed. Based on their intervention and treatment, patients were divided into operation group (n=7), chemotherapy group (n=8) and operation plus chemotherapy group (n=19). The clinical characteristics and treatment outcomes of the three groups were compared.
ResultsA statically significant difference was found in IRSG surgical-pathological stage among the three groups (P=0.026), while no significant difference existed in gender, age of disease onset, primary site, tumor size, pathological subtypes and IRSG risk group in the three groups (all P>0.05). In the operation group, three CR, one PR, one SD and two PD were achieved and one CR, one PR, one SD and five PD were obtained in the chemotherapy group. While in the chemotherapy plus operation group, four CR, twelve PR, one SD and two PD were achieved. A significant difference was found in response (P=0.043) and median overall survival (OS) (P=0.036) among the three groups, which were 44.7, 26.9 and 53.6 months, respectively.
ConclusionsPleomorphic RMS was the main histological subtype for adult RMS patients, and the prognosis for adult RMS was usually poorer than that for pediatric RMS patients. Single therapeutic approach could not achieve satisfactory outcomes, while multimodal treatment consisted of surgery, chemotherapy and radiotherapy are helpful to improve the prognosis of adult patients with RMS.
Key words:
Rhabdomyosarcoma; Adult; Clinicopathological characteristics; Multimodality treatment
Contributor Information
Qiankun Yang
Department of Bone and Soft Tissue Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital &
Institute, Shenyang 110042, China
Shenglong Li
Department of Bone and Soft Tissue Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital &
Institute, Shenyang 110042, China
Tong Chen
Department of Bone and Soft Tissue Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital &
Institute, Shenyang 110042, China
Zhongxiang Yao
Department of Physiology, the Army Medical University, Chongqing 400038, China
Xiaojing Zhang
Department of Bone and Soft Tissue Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital &
Institute, Shenyang 110042, China
